Syneos Health (SYNH) Getting Positive Press Coverage, Report Finds
Headlines about Syneos Health (NASDAQ:SYNH) have trended positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syneos Health earned a media sentiment score of 0.37 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.036231705243 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Company Sheet; Performance Check on Shares of Syneos Health, Inc. (:SYNH) as Beta Touches 0.83 (cantoncaller.com)
- Trading Spotlight on Shares of Syneos Health Inc. (SYNH) (zeelandpress.com)
- Stocks Highlights- Costco Wholesale Corporation (NASDAQ:COST), Syneos Health, Inc. (NASDAQ:SYNH), Calithera … (journalfinance.net)
- $1.12 Billion in Sales Expected for Syneos Health Inc (SYNH) This Quarter (americanbankingnews.com)
- Zacks: Brokerages Expect Syneos Health Inc (SYNH) to Post $0.68 Earnings Per Share (americanbankingnews.com)
Several analysts have recently weighed in on SYNH shares. Barclays reissued a “hold” rating and issued a $51.00 target price (up from $43.00) on shares of Syneos Health in a report on Friday, August 3rd. Mizuho reaffirmed a “hold” rating and set a $51.00 price objective on shares of Syneos Health in a research note on Monday, August 6th. ValuEngine raised Syneos Health from a “sell” rating to a “hold” rating in a research note on Thursday, July 5th. Zacks Investment Research raised Syneos Health from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Wednesday, May 16th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $60.00 price objective on shares of Syneos Health in a research note on Friday, August 3rd. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $52.78.
Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings data on Thursday, August 2nd. The company reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.01. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.09 billion. Syneos Health had a positive return on equity of 7.80% and a negative net margin of 4.32%. The firm’s quarterly revenue was up 315.5% on a year-over-year basis. equities research analysts expect that Syneos Health will post 2.41 earnings per share for the current fiscal year.
In other Syneos Health news, major shareholder H. Lee Equity Fund Vi Thomas sold 6,000,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $49.73, for a total transaction of $298,380,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.57% of the stock is owned by corporate insiders.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: Relative Strength Index
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.